Overview

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Collaborators:
Biogen
National Institutes of Health (NIH)
Treatments:
Antibodies, Monoclonal